Colorectal surgery obesity-related morbidity during COVID-19
Copyright © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved..
Tocilizumab, a monoclonal antiinterluekin-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe coronavirus disease 2019 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report was to present a case of acute large bowel perforation in a morbidly obese patient with coronavirus disease 2019 pneumonia who received empiric Tocilizumab. This case report analyzes the risks of acute large bowel perforation after using this medication empirically and discusses the appropriate management of this adverse event.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery - 16(2020), 9 vom: 24. Sept., Seite 1372-1375 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Montorfano, Lisandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 09.09.2020 Date Revised 11.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.soard.2020.06.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312993366 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312993366 | ||
| 003 | DE-627 | ||
| 005 | 20231225145620.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.soard.2020.06.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM312993366 | ||
| 035 | |a (NLM)32723601 | ||
| 035 | |a (PII)S1550-7289(20)30331-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Montorfano, Lisandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Colorectal surgery obesity-related morbidity during COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.09.2020 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Tocilizumab, a monoclonal antiinterluekin-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe coronavirus disease 2019 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report was to present a case of acute large bowel perforation in a morbidly obese patient with coronavirus disease 2019 pneumonia who received empiric Tocilizumab. This case report analyzes the risks of acute large bowel perforation after using this medication empirically and discusses the appropriate management of this adverse event | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Video-Audio Media | |
| 650 | 4 | |a Bowel perforation | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Colonic perforation | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a SARS-CoV-2 coronavirus | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Miret, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Asad Ur |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Mileydis |e verfasserin |4 aut | |
| 700 | 1 | |a Maron, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Mayank |e verfasserin |4 aut | |
| 700 | 1 | |a Ferri, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Bejarano, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Wexner, Steven D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery |d 2005 |g 16(2020), 9 vom: 24. Sept., Seite 1372-1375 |w (DE-627)NLM16493006X |x 1878-7533 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2020 |g number:9 |g day:24 |g month:09 |g pages:1372-1375 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.soard.2020.06.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2020 |e 9 |b 24 |c 09 |h 1372-1375 | ||